Covid-19 Update Debate
Full Debate: Read Full DebateNeale Hanvey
Main Page: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)Department Debates - View all Neale Hanvey's debates with the Department of Health and Social Care
(3 years, 2 months ago)
Commons ChamberWe are working on exactly that question. Of course, there is the question in advance of that of the vaccination of 12 to 18-year-olds, on which we are taking advice from the JCVI. We are conducting trials as to what are the best jabs to give, given which two previous jabs people have had, to give them the strongest protection. The third thing we are doing is working with AstraZeneca to develop a vaccine specifically targeted at the variants—that was part of the G7 work and announcements last week. If we can give a flu jab and a covid booster jab at the same time, that would be great. That is also under clinical evaluation, because, obviously, it would make the logistics so much easier over the autumn. Likewise, I am taking advice on which age groups and which groups it should be for: whether it should just be for the over-50s or for everybody; how to vaccinate; what group to put health and social care workers in; and whether there is a special regime for those who live in care homes, as there was in the first round of vaccination, where care home residents and staff came first. All of those are live questions on which we do not yet have answers, but that is the scope of the decisions we need to make ahead of the autumn for the autumn vaccination programme.
The progress with the vaccination roll-out is really to be welcomed and I give my thanks to all the staff, vaccinators and others who have been responsible for that progress. There are understandable concerns about how we manage and deal with variants, and my questions are centred on that today. What surveillance is taking place on the following measures or what is proposed? These are really important issues: the longevity of immunogenesis and how that is going to be captured; the adaptability of the virus and how that is going to be countered; and the need to modify or develop new vaccines as we progress into a position where the majority of the population are vaccinated.
I join the hon. Gentleman in congratulating all those involved in the vaccine roll-out, everywhere in the UK. In Scotland, it has been a remarkable effort, with the UK Government working with the Scottish Administration, the NHS across the country, local councils and the armed services—it has been a big team effort, and that has been part of the success of the vaccine roll-out.
The hon. Gentleman asked about three critical areas of the science. Reviews of all three areas are ongoing. They are led by Professor Jonathan Van-Tam, the deputy chief medical officer, whom the hon. Gentleman may have heard of, who is an absolutely brilliant clinician in this space—there are a lot more people involved who are doing excellent scientific work on these questions. That surveillance on immunogenicity, the work on the next-generation variant vaccine and the work on understanding the variants as we spot them is all going on. Public Health England has done a huge amount of work, working with public health colleagues right across the country, and I am grateful to them all.